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Background.We investigated serum testosterone and insulin-like growth factor 1 (IGF-1) levels’ associations with muscle fibre size
and resistance training in male dialysis patients.Methods.Male patients were included in a 16-week control period followed by 16
weeks of resistance training thrice weekly. Blood samples were obtained to analyse testosterone, luteinizing hormone (LH), IGF-1,
and IGF-binding protein 3. Muscle fibres’ size was analysed in biopsies from m. vastus lateralis. Results.The patients’ testosterone
levels were within the normal range at baseline (𝑛 = 20) (19.5 (8.2–52.1) nmol/L versus 17.6 (16.1–18.0), resp.) whereas LH levels
were higher (13.0 (5.5–82.8) U/L versus 4.3 (3.3-4.6), 𝑃 < 0.001, resp.). IGF-1 and IGF-binding protein 3 levels were higher in the
patients compared with reference values (203 (59–590) ng/mL versus 151 (128–276), 𝑃 = 0.014, and 5045 (3370–9370) ng/mL versus
3244 (3020–3983), 𝑃 < 0.001, resp.). All hormone levels and muscle fibre size (𝑛 = 12) remained stable throughout the study. Age-
adjusted IGF-1 was associated with type 1 and 2 fibre sizes (𝑃 < 0.05). Conclusion. Patients’ total testosterone values were normal
due to markedly increased LH values, which suggest a compensated primary insufficiency of the testosterone producing Leydig
cell. Even though testosterone values were normal, resistance training was not associated with muscle hypertrophy. This trial is
registered with ISRCTN72099857.
1. Introduction
Endogenous testosterone and insulin-like growth factor 1
(IGF-1) are important factors in muscle anabolism in terms
of stimulating muscle protein synthesis and inhibiting pro-
tein breakdown [1–3]. Thus, appropriate levels of anabolic
hormones, as well as their function, are important for the
avoidance of muscle atrophy, as well as the induction of
muscle hypertrophy in relation to resistance training.
In male patients who undergo dialysis due to chronic
kidney disease (CKD), serum testosterone levels are usually
below, or in the lownormal range, whilst luteinizing hormone
(LH) may be elevated [4–9]. Changes in androgen synthesis
and metabolism develop even with moderate reductions in
renal function and may be the result of primary hypogo-
nadism and/or disturbances in the hypothalamic-pituitary
axis [6]. Uraemic toxins, comorbidities, and several drugs are
believed to be contributory to the observed changes, but the
exact mechanism remains unclear [6].
In addition to altered testosterone levels, the growth
hormone action of muscle mRNA IGF-1 is also impaired
[10]. Low levels of these anabolic hormones in patients
undergoing dialysis affect muscle protein balance negatively
leading to a reduction in muscle strength and impaired
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physical function [11, 12].Whilst resistance training improves
muscle strength in dialysis patients [13] the impact of testos-
terone levels on resistance training and muscle fibre size
in these patients is generally unknown. We hypothesized
that serum testosterone levels at baseline were decreased
and associated with muscle fibre size in male patients
undergoing dialysis. The aim of this study was to investi-
gate association between resistance training and circulating
levels of serum testosterone and IGF-1. The study was reg-
istered on http://www.controlled-trials.com/ under number
ISRCTN72099857.
2. Materials and Methods
2.1. Participants. This study population comprised male
patients from a recent study of effects of resistance training
in dialysis patients conducted by us, where the primary out-
comes were changes in quality of life, physical performance,
and both muscle power and strength [13]. The men were
included from three dialysis centres in or around the capital
of Demark, to a control period of 16 weeks without any
intervention followed by an intervention period of 16 weeks
with resistance training.The inclusion criteria were age above
18 years, undergoing haemodialysis or peritoneal dialysis for
more than three months, and the ability to participate in
the training programme. Exclusion criteria were testosterone
inhibiting medical treatment, insulin therapy, severe diabetic
retinopathy, amputation of a lower limb, severe peripheral
polyneuropathy, dementia, inability to speak Danish, and
participation in other conflicting trials.
Data concerning renal disease and morbidity were
obtained from case records, and levels of comorbidity were
assessed usingThe Index of Coexistent Disease [14]. All tests
were performed identically with regard to the dialysis pro-
cedure for each individual, before and after the control and
training period to minimize interdialytic variation. Informed
consent was obtained from all the patients and the local
ethical committee approved this protocol (H-D-2008-124).
2.2. Intervention. The training programme has been
described recently [13]. In brief, it consisted of supervised
heavy load resistance training three times weekly for 16
weeks. The training began with 5 minutes of warm-up
followed by up to 5 sets of leg press, leg extension, and leg
curl.The rest period between each set was 60–90 seconds (the
time between repetitions was not regulated).The programme
was progressive and the load was increased according to
increased muscle strength during the training period with a
corresponding decrease in repetitions maximum from 15 to
6. Every set was performed to exhaustion.
2.3. Hormone Analyses. Blood samples were obtained in
the morning hours after an overnight fast, a minimum
of 18 hours after a training session. Serum was separated
and kept frozen at −80∘ until analysis. Levels of testos-
terone, estradiol, LH, follicle-stimulating hormone (FSH),
and sex hormone-binding globulin (SHBG) were analysed
by fluoroimmunometricmethods (Autodelfia,Wallac, Turku,
Finland) and inhibin-B by an enzyme-linked immunosor-
bent assay (Inhibin-B GenII, Beckman Coulter, USA). IGF-1
and insulin-like growth factor-binding protein 3 (IGF-BP3)
levels were determined by a chemiluminescence based assay
(Immulite 2000, SiemensHealthcareDiagnostics, Tarrytown,
USA).
The intra- and interassay coefficient of variation (CV) for
measurement of testosterone were <2% and 8%, respectively.
For estradiol<4% and 8%, for both LH and FSH<2% and 6%,
SHBG <5% and <9%, inhibin-B <3% and <13%, IGF-1 <2%
and <12%, and IGF-BP3 <4% and 11%, respectively.The limits
of detection (LODs) were testosterone 0.3 nmol/L, estradiol
70 pmol/L, LH 0.05 IU/L, FSH 0.05 IU/L, SHBG 0.23 nmol/L,
inhibin-B 3 pg/mL, IGF-1 20 ng/mL, and IGF-BP3 100 ng/mL.
Free testosterone levels were calculated from total testos-
terone, SHBG, and albumin as described previously [15]. For
the reference population we used a fixed albumin level of
43.8 g/L when free testosterone was determined. Hormone
ratios were calculated by simple division.
2.4. Muscle Fibre Analyses and ATPase Histochemistry. The
muscle fibre analyses and ATPase histochemistry have been
described in detail elsewhere [13]. Muscle biopsies were
obtained from the mid-region ofm. vastus lateralis, mounted
with Tissue-Tek (Sakura Finetek, Zoeterwoude, The Nether-
lands), and immediately frozen in isopentane cooled in liquid
nitrogen and stored at −80∘C until analysis. Serial sections
(10 𝜇m) from themuscle biopsy sampleswere cut andmyofib-
rillar ATPase histochemistry was performed at pH 9.40 after
preincubation at pH 4.37, 4.60, and 10.30 [16]. Computer
image analysis was performed using an image analysis system
(TEMA, Scan Beam ApS, Hadsund, Denmark). Fibre sizes
were classified as major type 1 and type 2 [17]. Only truly
horizontally cut fibres were included in the fibre size analyses.
2.5. Muscle Strength. Maximal voluntary knee extension was
tested in an adjustable dynamometer chair (Good Strength,
Metitur Ltd., Jyva¨skyla¨, Finland) at a knee angle of 60∘
from full extension. The patients were instructed to rapidly
produce asmuch force as possible and hold it for 5 seconds. A
minimum of three tests separated by 60 seconds of rest were
conducted. For each subject the best performance with the
highest value followed by a lower value was accepted as the
result. The results were digitized into Newton (N) using the
Good Strength software package (version 3.11. Metitur Ltd.,
Jyva¨skyla¨, Finland).
2.6. Blinding. The investigators who analysed the muscle
morphology and hormone levels of the subjects were blinded
to any other subject information, including the outcomes.
2.7. Statistical Analyses. Statistical analyses were carried out
using IBM SPSS Statistics 19. The data distributions were
tested using the Shapiro-Wilks test andQ-Qplots.Most resid-
uals were found not to be normally distributed and statis-
tical analyses were performed using nonparametric tests.The
Wilcoxon Signed Ranks test was used to test for differences
between baseline test and pretraining test (control period),
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Figure 1: Study design and dropout.
between pretraining test and posttraining test (training
period), and in-between periods. The Mann-Whitney test
was used to compare the patients’ data with data from the
male reference population. The male reference population’s
hormone values were calculated using the patients’ age
as weights. The reference did not comprise LH, FSH, and
testosterone/LH data for men older than 70 years and in
these variables patients’ data were compared with data for
70-year-old men from the reference population.
Binary correlations were tested using the Spearman test.
Age adjustments were performed using linear regression
analyses. In the linear regression analyses variables were
included if 𝑃 < 0.1 in binary correlations and variables
were log-transformed if the residuals were not normally
distributed.
Data are presented as themedian (range),mean (standard
deviation—SD), 𝑡, coefficients (95% confidence interval—
CI), counts, or percentages. All tests were two-tailed and the
level of significance was taken as 𝑃 ≤ 0.05.
3. Results
Twenty patients were initially included in the study and 12
(haemodialysis, 𝑛 = 11; peritoneal dialysis, 𝑛 = 1) completed
the intervention (see Figure 1). Dropout during the control
period (𝑛 = 5) and during the training period (𝑛 = 3) was
due to medical complications not related to the study. The
patients who dropped out did not differ with regard to age,
pretested comorbidity level, body mass index, or hormone
profile compared to those who completed the study. The
patients’ characteristics are presented in Tables 1 and 2.
Hormone profiles at baseline for the included patients
are presented in Table 2 together with all the available data
from the age-matched reference males. The patients’ total
testosterone was similar to the male reference and correlated
negatively with age (𝑟 = −0.456, 𝑃 = 0.04) (Figure 2). Free
testosterone was elevated in the patients compared to the
reference (Table 2). For all patients the LH values exceeded
the age-matched means for the references (Figure 3), and
within the patient group the correlation between LH and
age was 𝑟 = 0.555, 𝑃 = 0.011. IGF-1 and IGF-BP3 were
significantly higher in the patients compared to the reference
group (Table 2), whereas IGF-1/IGF-BP3 did not differ. In
correlations between the patients’ testosterone and IGF-1, free
testosterone was found to be positively associated with IGF-1
(𝑟 = 0.644, 𝑃 = 0.002).
All hormones were found to be unchanged between
baseline and the end of the training period. However, a
significant change in total testosterone/LH was found when
the delta values of the control period and the training period
Table 1: Characteristics of the participants.
Characteristic (𝑛 = 20)
Age (years) 65 (26–74)
Dialysis modality (HD/PD) 19/1
Duration of chronic dialysis (years) 3.4 (1.1–15.0)
Comorbidities (score 0–3) 3 (1–3)
Body mass index (kg/m2) 25.6 (18.1–33.5)
Haemoglobin (mmol/L) 7.4 (6.4–9.9)
Albumin (g/L) 42.1 (37.4–49.8)
C-reactive protein (mg/L) 4.0 (0.6–23.0)
Phosphate (mmol/L) 1.8 (0.9–2.4)
Bicarbonate (mmol/L) 25 (17–33)
Primary renal disease
Type 2 diabetes 1
Hypertension 3
Polycystic kidneys 4
Glomerulonephritis 7
Nephrosclerosis 1
Other/unknown 4
HD: haemodialysis; PD: peritoneal dialysis. Data are presented as median
(range) or count.
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Figure 2: Testosterone levels plotted against the age of the patients.
The dots represent male patients undergoing dialysis. Curves are
mean ± 2SD for a male reference population.
were compared (∼−15% versus +17%, resp.) as presented in
Table 3. Body mass index, haemoglobin, albumin, C-reactive
protein, phosphate, and bicarbonate remained unchanged
throughout the study.
Muscle fibre sizes remained unchanged during the study
whereas muscle strength increased significantly by 19–25%
during the training period (Table 4).
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Table 2: Hormone levels for the patients (𝑛 = 20) and for the age-matched male reference population.
Variables All patients (𝑛 = 20) Reference population P
Total T (nmol/L) 19.5 (8.2–52.1) 17.6 (16.1–18.0) 0.174
Free T (pmol/L) 473 (174–1057) 289 (226–377) 0.004
IGF-1 (ng/mL) 203 (59–590) 151 (128–276) 0.014
IGF-BP3 (ng/mL) 5045 (3370–9370) 3244 (3020–3983) <0.001
IGF-1/IGF-BP3 0.0443 (0.0158–0.0630) 0.04652 (0.0400–0.0694) 0.102
SHBG (nmol/L) 42.0 (8.0–132.0) 48.0 (32.9–59.4) 0.211
LH (U/L) 13.0 (5.5–82.8) 4.3 (3.3–4.6) <0.001
FSH (U/L) 9.7 (1.7–86.1) 7.0 (3.3–7.5) 0.091
Total T/LH 2.1 (0.2–5.0) 4.1 (3.6–5.5) <0.001
Estradiol (pmol/L) 105 (75–133) 117 (94–123) 0.096
Inhibin-B (pg/mL) 170 (1–403) 142 (134–165) 0.659
Inhibin-B/FSH 18.7 (0.1–235.7) 20.3 (17.9–49.0) 0.445
Data are presented as median (range). T: testosterone; SHBG: sex hormone-binding globulin.
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Figure 3: Luteinizing hormone levels plotted against the age of
the patients. The dots represent male patients undergoing dialysis.
Curves are mean ± 2SD for a male reference population.
3.1. Testosterone and IGF-1 Correlated with Muscle Fibre Size.
In unadjusted binary correlations between baseline tested
anabolic hormones and muscle fibre size, free testosterone
was found to be positively associated with type 2 muscle
fibre size (𝑟 = 0.525, 𝑃 = 0.025), whereas age-adjusted
free testosterone was neither significantly associated with
type 1 nor significantly associated with type 2 muscle fibre
size (Table 5). Total testosterone was not associated with any
muscle fibre size. Unadjusted IGF-1 was positively associated
with type 1 fibre size (𝑟 = 0.626, 𝑃 = 0.005) and type 2 fibre
size (𝑟 = 0.598, 𝑃 = 0.009). When IGF-1 was age-adjusted
it remained associated with type 1 fibre size (𝑃 = 0.005) and
type 2 fibre size (𝑃 = 0.012) (Table 5).
Prior to the training, hormone levels including total
testosterone, free testosterone, testosterone/LH, and LHwere
not associated with individual changes in muscle fibre size
during the training period (data not shown).
4. Discussion
To the best of our knowledge, this is the first study to
investigate testosterone levels during a resistance training
program in dialysis patients.The patients’ serum testosterone
levels were not different from those of a reference population
whereas LH levels were markedly elevated, indicating a
compensated primary Leydig cell insufficiency, a finding that
has not been reported in recent studies but was reported in
studies published in the 1970s [7]. Even though the testos-
terone values were within the normal range, the resistance
training was not associated with muscle hypertrophy.
Our finding of normal total testosterone levels in the
patient group is in contrast to the results of other studies
that have detected relatively lower levels of testosterone in
dialysis patients [4, 5, 8, 9]. Our study does not provide
an explanation for this discrepancy, but we speculate that
the results in our patient group may be indicative of a
selected healthier subgroup of patients than previously pub-
lished work. This speculative interpretation may, however,
be supported by the patients’ motivation to participate in a
comprehensive training program. An increased LH level as a
response to decreased Leydig cell capacity is an example of
the classical endocrine feedback loop where the endocrine
system tends to keep the peripheral hormones at a steady
level. In our dialysis patients the decreased Leydig cell
capacity was compensated by an increased LH stimulation.
However, in general, somemen go frombeing eugonadal (i.e.,
having normal testosterone levels on a background or normal
LH levels) to having a compensated hypogonadism as our
patients. Some patientsmay further develop an overt primary
hypogonadism where an increased LH level is insufficient
to compensate for the decreasing Leydig cell capacity as
suggested by the European Male Aging Study [18]. The
findings of reduced testosterone levels in previous studies
of dialysis patients may reflect that these in general have
reached the stage of primary hypogonadism. It is most likely
the impaired kidney function in the dialysis patients that
causes the decreasing Leydig cell capacity. To our knowledge
it remains to be established to which degree testosterone
deficient dialysis patients will benefit from a testosterone
substitution therapy. However, it is tempting to speculate
that they will benefit as many of the classical symptoms
[18] between these two diseases overlap. Thus, our findings
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Table 3: Hormone levels for those patients who completed the intervention (𝑛 = 12). The 16-week control period was measured from the
baseline test to the pretraining test, and the 16-week training period was measured from the pretraining to the posttraining test.
Variables Baseline (𝑛 = 12) Pretraining (𝑛 = 12) Posttraining (𝑛 = 12) P controlperiod
P training
period
P between
periods
Total T (nmol/L) 21.7 (8.2–52.1) 18.7 (7.8–54.7) 19.8 (7.2–57.7) 0.695 0.326 0.099
Free T (pmol/L) 485 (141–1057) 474 (177–820) 524 (240–776) 0.695 0.530 0.347
IGF-1 (ng/mL) 203 (138–590) 246 (108–811) 201 (113–606) 0.346 0.272 0.388
IGF-BP3 (ng/mL) 4905 (3600–9370) 4740 (3610–9760) 4525 (3550–8900) 0.754 0.844 0.937
IGF-1/IGF-BP3 0.0443 (0.0313–0.0630) 0.0461 (0.0262–0.0831) 0.0423 (0.0267–0.0895) 0.433 0.182 0.347
SHBG (nmol/L) 42.5 (13.0–66.0) 35.0 (11.0–80.0) 38.5 (8.0–83.0) 0.235 0.366 0.239
LH (U/L) 13.4 (5.5–57.2) 15.8 (5.6–58.7) 14.4 (5.5–52.0) 1.000 0.424 0.477
FSH (U/L) 10.5 (4.1–86.1) 9.7 (3.9–84.0) 8.9 (3.3–83.7) 1.000 0.272 1.000
Total T/LH 1.83 (0.18–5.01) 1.55 (0.24–2.86) 1.82 (0.34–3.70) 0.084 0.110 0.041
Estradiol (pmol/L) 101 (75–133) 104 (70–113) 101 (68–125) 0.432 0.694 0.638
Inhibin-B (pg/mL) 170 (1–342) 162 (1–380) 172 (1–355) 0.929 0.721 0.575
Inhibin-B/FSH 15.35 (0.01–83.82) 15.77 (0.01–88.99) 20.31 (0.01–107.90) 0.937 0.136 0.209
Data are presented asmedian (range). T: testosterone; SHBG: sex hormone-binding globulin;DHEA: dehydroepiandrosterone; AMH: anti-Mu¨llerian hormone.
Table 4: Muscle fibre size and muscle strength for those patients who completed the intervention (𝑛 = 12). The control period was between
the baseline and pretraining test. The training period was between the pretraining and the posttraining test.
Variables Baseline Pretraining Posttraining
Muscle fibre size
Type 1 (𝜇m2) 4896 (3138–8453) 4760 (2853–7891) 4730 (2273–9204)
Type 2 (𝜇m2) 3485 (2778–6067) 3246 (2284–5336) 3832 (2829–6953)
Knee extension strength
Right (N) 349 (195–511) 349 (200–583) 460 (258–695)∗∗∗
Left (N) 299 (216–595) 341 (193–558) 400 (238–657)∗∗
Data are presented as median (range). N: Newton. Between pretraining and posttraining ∗∗P < 0.010; ∗∗∗P < 0.005.
encourage a more detailed investigation focussing on this
aspect.
Testosterone was unchanged after training and this was
not surprising since the baseline values were relatively high.
Testosterone/LH was also found to be unchanged after train-
ing. However, the statistical analyses showed a significant
difference between delta values when comparing the control
period with the training period. A slight decrease over
the control period was followed by a slight increase over
the training period in terms of the testosterone/LH value,
resulting in a 32% net increase. This finding is most likely
a chance finding, being the result of normal variation in
testosterone. On the other hand, it cannot be excluded that
a decrease in testosterone/LH in the patient sample was
counteracted by a reverse through training. If this is indeed
a true effect of training, then the underlying mechanism is
not obvious. If the decrease in testosterone/LH was a true
finding, it could be the result of improvedmetabolism leading
to an improved testes function. However, further studies are
needed beforewe are able to drawmore definitive conclusions
about such a relation.
The training intervention was not associated with muscle
hypertrophy at the fibre level, which was an unexpected
result. One would expect hypertrophy after a period of high
load resistance training [19] especially when testosterone
values are within a normal range. Indeed, the effect of
resistance training on muscle mass is in general associated
with testosterone level [20]. In healthy young men who
conducted resistance training, an increase in muscle mass
was significantly greater in subjects with normal testosterone
compared to subjects with a suppressed testosterone level
[20].The anabolic effect of the training in our studymay have
been counteracted by impaired muscle protein synthesis or
increased protein breakdown due to comorbidities [21, 22],
as well as regular dialysis treatment [23]. Thus the significant
effect on muscle strength observed in these patients may be
primarily the result of neuromuscular improvements [24].
However, our studymayhave a relatively low statistical power,
and one cannot ignore the possibility that the unchanged
muscle fibre size that was observed could be the result of a
type II error.
The relatively high levels of circulating IGF-1 and IGF-
BP3 are in line with another study of resistance training in
dialysis patients [25], although a decrease in IGF-1 following
resistance training has also been reported [26]. Our finding
of a positive association between IGF-1 and muscle fibre size
at baseline is supported by MacDonald and colleagues who
found a positive correlation between lean body mass and
circulating IGF-1 in dialysis patients [27]. Whether circulat-
ing IGF-1 has a more significant role in muscle anabolism
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Table 5: Age adjusted free testosterone and IGF-1 correlations with muscle fibre size (dependent variables).
Muscle fibre size Free testosterone (pmol/L) IGF-1 (ng/mL)
t Coefficient∗ (95% CI) P t Coefficient∗ (95% CI) P
Type 1 (𝜇m2) 1.61 0.00 (0.00-0.00) 0.128 3.29 0.35 (0.12–0.58) 0.005
Type 2 (𝜇m2) 1.83 1.596 (−0.259–3.450) 0.087 2.84 2348 (586–4110) 0.012
∗Unadjusted. CI: confidence interval.
in patients undergoing dialysis compared to healthy subjects
remains unknown.
The present study has important limitations. The sample
size was small and heterogeneous in terms of age and dialysis
duration. Furthermore, we did not measure body compo-
sition using scanning methods, which would have been
interesting in addition to the data for muscle size at the fibre
level. Finally, the study was limited by the nonrandomised
design as a time series design was used. The design was
used to elevate the number of patients, who received the
intervention. However, a considerable strength of this study
is that it presents data from a rigorous relatively long period
of resistance training.
In conclusion, well treatedmale patients undergoing dial-
ysis may counteract impaired Leydig cell function through
elevated LH secretion. Even though testosterone and IGF-
1 values were in or above the normal range for healthy
individuals, the patients did not achieve muscle hypertrophy
after a rigorous period of high load resistance training.
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